Lastly, AML and myelodysplastic syndrome (MDS) are often defined by atypical splicing of known AML oncogenic drivers, including FLT3 and NOTCH2 (49, 50), suggesting these tumors may be acutely sensitive to the targeting of the splicing machinery. The gene discussed is FLT3; the disease is myelodysplastic syndrome.